Anti-oestrogenic prevention of breast cancer--the make or break point.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12360281.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical trials have shown that giving anti-oestrogens to healthy women can reduce the early incidence of breast cancer by approximately 40%. However, the large numbers of women treated, compared with the few who get breast cancer, together with the not insignificant toxicity and the unknown long-term clinical benefits and risks, makes this strategy of prevention versus treatment precarious. So how can we improve the odds for the successful use of endocrine chemoprevention?
Medical subject headings
- Antineoplastic Agents, Hormonal
- Breast Neoplasms
- Estrogen Receptor Modulators